Efficacy of intravenous morphine patient-controlled analgesia in the treatment of refractory cancer pain
Objective To observe the clinical efficacy of intravenous morphine patient-controlled analgesia(PCA)in the treatment of refractory cancer pain.Methods A total of 106 patients with refractory cancer pain were randomly divided into two groups and treated with intravenous morphine hydrochloride PCA(group A,52 cases)and with oral morphine hydrochloride sustained-release tablets(group B,54 cases).The treatment lasted for 5 days.The scores of numerical rating scale(NRS)were evaluated before and on the 1st,3rd and 7th day during treatment.The number of explosive pain attack was recorded.The adverse reactions of the two groups within 7 days during treatment were observed.Results The NRS score and the number of explosive pain attack in group A were decreased on the 1st,3rd and 7th day during treatment,which were better in group A than those in group B(P＜0.05 or P＜0.01).The incidences of adverse reactions of the two groups were similar within 7 days of the treatment(P＞0.05).Conclusion Intravenous morphine PCA in the treatment of refractory cancer pain has better clinical efficacy than oral morphine with mild adverse effects.
Refractory cancer painPatient-controlled analgesiaMorphine
NETL
NSTL
万方数据
